This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic

What Have We Learned in the Last 10 Years?

Judith A. Hinchey, MD, MS

Arch Neurol. 2008;65(2):175-176.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of the Archives, Lee et al¹ present the largest series of patients with reversible posterior leukoencephalopathy syndrome (RPLS) to date and a review of the literature. The first series of patients was reported in 1996, and this gives us an opportunity to review what we have learned about this condition since then, including the proposed alternate name posterior reversible encephalopathy syndrome.^2-3

The largest effects during the last 10 years have been on the improvement in neuroimaging diagnostics and an extension of the list of causes associated with RPLS.

CAUSES

There have been so many new medications or disease states linked to RPLS that it is not possible to enumerate them here. Most are chemotherapeutic agents, immunosuppressive medications, or cytotoxic treatments for malignant neoplasms or immunologically based conditions.⁴ There have also been many more cases reported in normotensive patients not receiving chemotherapeutic medications, . . . [Full Text of this Article]

NEUROIMAGING

CLINICAL SPECTRUM

MECHANISM

AUTHOR INFORMATION

RELATED ARTICLE

Clinical Spectrum of Reversible Posterior Leukoencephalopathy Syndrome
Vivien H. Lee, Eelco F. M. Wijdicks, Edward M. Manno, and Alejandro A. Rabinstein
Arch Neurol. 2008;65(2):205-210.
ABSTRACT | FULL TEXT